mir 329 restricts tumor growth by targeting grb2 in pancreatic cancer
Pancreatic cancer is one of the most lethal malignancies worldwide. To illustrate the pathogenic mechanism(s) we looked into the expression and function of miR 329 associated with pancreatic cancer development. It was found that miR 329 expression was downregulated in the pancreatic cancer patients who demonstrated significantly shorter overall survival than the patients having upregulated expression. Also, more advanced pT stage cases were observed in the low miR 329 expression group of patients. Interestingly, our studies uncovered that miR 329 overexpression inhibited proliferation and induced apoptosis of pancreatic cancer cells, in contrast the miR 329 inhibitor reversed this phenomenon dramatically. Additionally, overexpression of miR 329 significantly limited tumor growth in the xenograft model. In the mechanistic study, we identified GRB2 as a direct target of miR 329 in pancreatic cancer cells, and expression of GRB2 was inversely correlated with miR 329 expression in pancreatic cancer patients. Furthermore, GRB2 overexpression in cell line and xenograft model dramatically diminished miR 329 mediated anti proliferation and apoptosis induction, indicating that GRB2/pERK pathway was mainly downregulated by miR 329 expression. In general, our study has shed light on miR 329 regulated mechanism and, miR 329/GRB2/pERK is potential to be targeted for pancreatic cancer management.
Oncotarget